Biotech Values

[DewDiligence]

> VPHM – my earlier concern was based on TSH levels from the monotherapy trial. I was surprised, since TSH is commonly, adversely, affected by interferon.<

Understood—I nevertheless thought your post was important enough to reiterate given that the safety data from the combo portion of the trial remain blinded.

I may be barking up the wrong tree, but VPHM’s comments in today’s PR about safety and viral rebound do not exactly inspire confidence.